Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.05m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Directorate Change

29 Nov 2018 10:37

RNS Number : 9093I
Maven Income & Growth VCT PLC
29 November 2018
 

Maven Income and Growth VCT PLC (the Company)

 

Directorate Changes

 

As announced on 26 September 2018, alongside the publication of the Prospectus for the Offer for Subscription, the Board now confirms that Fiona Wollocombe will resign as a Non-executive Director of the Company with effect from 24 January 2019. Mrs Wollocombe has been a Director of the Company since 20 May 2004, serving as its Chairman from 7 July 2005 until 8 July 2010, and the Board wishes to record its gratitude for the significant contribution Fiona made during her time in office and extends to her its best wishes for the future.

 

The Board is also pleased to announce the appointments of Dr Alison Fielding and Dr Andrew Harrington as Non-executive Directors, each with effect from 1 January 2019. Both of these new Directors will also serve on the Company's Audit, Management Engagement, Nomination, Risk and Remuneration Committees, and will stand for election by Shareholders at the Annual General Meeting to be held in July 2019

 

Dr Fielding is an experienced entrepreneur, senior executive and non-executive director, with a track record of leading strategy within both large and small organisations to set direction, evaluate options, implement plans and drive performance. She is currently a venture partner at IP Group plc, with her role there including two non-executive directorships with portfolio companies; Perachem Holdings plc, of which she is chairman, and Getech Group plc, where she chairs the audit committee.

 

Alison has held a number of other non-executive roles and her other current appointments include non-executive directorships of Nanoco Group plc and Queen Mary Innovation Limited, and serving as a trustee of the Royal Voluntary Service and the Carnegie Trust for the Universities of Scotland.

 

Dr Harrington is co-owner of AHV Associates LLP, which was formed in 2001 and works alongside management teams and shareholders across many sectors to advise on transactions, such as the purchase or sale of companies and capital raising.

 

Andrew was previously founder and chief executive of Nextcall Telecom, a business backed by venture and private investor capital, before which he was managing director at Salomon Brothers, where he advised on investment, IPOs, secondary public market offerings and mergers & acquisitions.

 

In relation to both of these new appointments, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

 

Maven Capital Partners UK LLP

Secretary

29 November 2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGGQWGUPRGUB
Date   Source Headline
6th Jul 20233:37 pmRNSNet Asset Value
6th Jul 20231:06 pmRNSResult of AGM
7th Jun 20234:21 pmRNSAnnual Financial Report
2nd Jun 20239:39 amRNSIssue of Equity
1st Jun 202312:18 pmRNSNet Asset Value(s)
26th May 20233:53 pmRNSTransaction in Own Shares
24th May 202310:52 amRNSUnaudited NAV and Proposed Final Dividend
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
5th Apr 202312:33 pmRNSDirector/PDMR Shareholding
5th Apr 202312:26 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
3rd Mar 202310:37 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 20239:47 amRNSIssue of Equity
21st Feb 20234:39 pmRNSTransaction in Own Shares
6th Feb 20234:23 pmRNSNet Asset Value(s)
2nd Dec 20229:30 amRNSIssue of Equity
25th Nov 202212:36 pmRNSStatement re Dividend Investment Scheme
9th Nov 20222:34 pmRNSResult of General Meeting
4th Nov 202211:15 amRNSHalf-year Report
26th Oct 20223:50 pmRNSTransaction in Own Shares
14th Oct 20223:33 pmRNSNet Asset Value and Interim Dividend
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
5th Aug 20224:39 pmRNSTransaction in Own Shares
15th Jul 202211:08 amRNSIssue of Equity
11th Jul 20223:12 pmRNSStatement re Dividend Investment Scheme
8th Jul 20223:28 pmRNSStatement re Joint Offers for Subscription
8th Jul 20222:36 pmRNSNet Asset Value(s)
7th Jul 20222:34 pmRNSResult of AGM
8th Jun 20222:12 pmRNSAnnual Financial Report
29th Apr 20222:28 pmRNSTransaction in Own Shares
27th Apr 20224:04 pmRNSTransaction in Own Shares
21st Apr 202211:22 amRNSStatement re NAV and Proposed Final Dividend
25th Jan 20224:04 pmRNSTransaction in Own Shares
21st Jan 20223:15 pmRNSNet Asset Value(s)
3rd Dec 20219:48 amRNSIssue of Equity
26th Nov 20219:53 amRNSStatement re Dividend Investment Scheme
12th Nov 20214:31 pmRNSHalf-year Report
11th Nov 20214:23 pmRNSTransaction in Own Shares
9th Nov 20211:33 pmRNSTransaction in Own Shares
27th Oct 20214:44 pmRNSNet Asset Value and Interim Dividend
20th Sep 20214:57 pmRNSStatement re Change of Registrar
16th Jul 202110:04 amRNSIssue of Equity
12th Jul 20214:28 pmRNSStatement re Dividend Investment Scheme
7th Jul 20213:32 pmRNSNet Asset Value(s)
7th Jul 202112:37 pmRNSResult of AGM
4th Jun 20214:16 pmRNSAnnual Financial Report
4th May 20213:37 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.